Screening for Cystic Fibrosis Related Complications in the Context of a Pandemic and Altered Models of Care
Background: Standard of care recommend that patients with cystic fibrosis (CF) require screening investigations to assess for complications. Changing models of care due to the COVID19 pandemic may have impacted completion of recommended screening. Objective: To compare the frequency of screening inv...
Main Authors: | Michael Doumit, Roxanne Strachan, Raynuka Lazarus, Peter Middleton, Ruth Dentice, Jessica Marouvo, Laura Jeffrey, Hiran Selvadurai, Sheila Sivam, Verity Pacey, Adam Jaffe, Kelly Gray |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2023-10-01
|
Series: | Health Services Insights |
Online Access: | https://doi.org/10.1177/11786329231205145 |
Similar Items
-
Single-arm, open-labelled, safety and tolerability of intrabronchial and nebulised bacteriophage treatment in children with cystic fibrosis and Pseudomonas aeruginosa
by: Adam Jaffe, et al.
Published: (2023-07-01) -
Avatar acceptability: views from the Australian Cystic Fibrosis community on the use of personalised organoid technology to guide treatment decisions
by: Laura K. Fawcett, et al.
Published: (2021-01-01) -
The changing epidemiology of pulmonary infection in children and adolescents with cystic fibrosis: an 18-year experience
by: Jagdev Singh, et al.
Published: (2024-04-01) -
Expression of PPARγ and paraoxonase 2 correlated with Pseudomonas aeruginosa infection in cystic fibrosis.
by: Phoebe E Griffin, et al.
Published: (2012-01-01) -
Cystic fibrosis modulator therapy can reverse cystic bronchiectasis
by: Peter G. Middleton, et al.
Published: (2023-07-01)